Results 71 to 80 of about 918 (92)

Radioactivity levels in the saliva of patients undergoing targeted radioligand therapy with [¹⁷⁷Lu]Lu-PSMA-I&T and [¹⁷⁷Lu]Lu-DOTA-TOC. [PDF]

Clin Oral Investig
Schedeit C, Gözlügöl N, Alsheikh RS, Shelan M, Seifert R, Caobelli F, Borner U, Iizuka T, Schaller B, Rominger A, Cumming P, Afshar-Oromieh A, Zeimpekis KG.   +12 more
europepmc   +1 more source

Enhancing PRRT Outcome Prediction in Neuroendocrine Tumors: Aggregated Multi-Lesion PET Radiomics Incorporating Inter-Tumor Heterogeneity. [PDF]

Cancers (Basel)
Sabouri M, Hajianfar G, Gharibi O, Rafiei Sardouei A, Menda Y, Dundar A, Gadens Zamboni C, Jain S, Kruzer M, Zaidi H, Yousefirizi F, Rahmim A, Shariftabrizi A.   +12 more
europepmc   +1 more source

Clinical practice guidelines for the management of non-functioning advanced GEP-NENs: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology (AIOM) in collaboration with the Italian Association for Neuroendocrine Tumors (ITANET). [PDF]

ESMO Open
Spada F, Gelsomino F, Rinzivillo M, Cinquini M, Fittipaldo VA, Tralongo A, Moschetti I, Albertelli M, Ambrosini V, Amoroso V, Antonuzzo L, Badalamenti G, Bajetta E, Baldari S, Barberis M, Berruti A, Bertani E, Bonomo G, Bodei L, Buzzoni R, Brizzi MP, Campana D, Capurso G, Casadei R, Castellano M, Cingarlini S, Cives M, Colao AM, Coppa J, Cremonini N, Davì MV, De Angelis CG, de Braud F, De Robertis R, Faggiano A, Falconi M, Fassan M, Ferolla P, Ferone D, Filice A, Fiore F, Funicelli L, Granata V, Giuffrida D, Grana CM, Grimaldi F, Ibrahim T, La Salvia A, Laghi A, Luppi G, Maccauro M, Marconcini R, Massironi S, Mazzaferro V, Merola E, Milione M, Modica R, Ortolani S, Papotti MG, Partelli S, Pelosi G, Pusceddu S, Ramundo V, Ravizza D, Razzore P, Reimondo G, Ricci C, Rindi G, Rizzo FM, Rossi RE, Tafuto S, Tiberio GAM, Versari A, Vigorito R, Zatelli MC, Di Maio M, Perrone F, Cinieri S, Panzuto F, Fazio N.   +79 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Estimate of activity discharged into the sewer network in neuroendocrine treatments with 177Lu-DOTA-TATE

Applied Radiation and Isotopes, 2022
The urine of patients treated for neuroendocrine tumors with 177Lu is a liquid radioactive waste. The total body activity retained by the patient is quantified with SPECT-CT image 1 day after administration. From the activity of 177Lu in patient after 1 day Apat_Lu177_1d, the activity in urine after 1 day Aurine_Lu177_1d is determined, as well as the ...
Raquel Barquero, Javier Velasco, Carlos Andres, Ricardo Torres, Ricardo Ruano   +4 more
openaire   +2 more sources

Repeated cycles of peptide receptor radionuclide therapy (PRRT) – Results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET

Radiotherapy and Oncology, 2012
PRRT is a known tool in the management of patients with disseminated and inoperable NETs. The aim of study was to assess the effectiveness of the repeated cycles of PRRT in patients with disseminated and inoperable NETs.Eighty nine patients were included in the PRRT.
Dorota, Pach, Anna, Sowa-Staszczak, Jolanta, Kunikowska, Leszek, Królicki, Małgorzata, Trofimiuk, Agnieszka, Stefańska, Monika, Tomaszuk, Bogusław, Głowa, Renata, Mikołajczak, Dariusz, Pawlak, Agata, Jabrocka-Hybel, Alicja B, Hubalewska-Dydejczyk   +11 more
openaire   +2 more sources

Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy

European Journal of Nuclear Medicine and Molecular Imaging, 2013
Peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin analogues has been demonstrated to be an effective therapeutic option in patients with disseminated neuroendocrine tumours (NET). Treatment with tandem [(90)Y]DOTA-TATE and [(177)Lu]DOTA-TATE may improve the efficacy of PRRT without increasing the toxicity. In a phase II study
E. Seregni, M. Maccauro, C. Chiesa, L. Mariani, C. Pascali, V. Mazzaferro, F. De Braud, R. Buzzoni, M. Milione, A. Lorenzoni, A. Bogni, A. Coliva, S. Lo Vullo, E. Bombardieri   +13 more
openaire   +2 more sources

[A Report on Health Resource Use in Internal Radiation Therapy Using 177Lu-DOTA-TATE].

Kaku igaku. The Japanese journal of nuclear medicine, 2021
Internal radiation therapy using lutetium-177(177Lu)-DOTA-TATE injection will be applied in actual clinical practice soon. However, the NHI medical technical fee for the use of 177Lu-DOTA-TATE injection has not yet been set. The Japanese Society of Nuclear Medicine surveyed health resource use in internal radiation therapy using 177Lu via ...
Katsuhiko, Kato, Soichi, Nakamura, Yoshinori, Matoba, Seigo, Kinuya   +3 more
openaire   +1 more source

‘Reverse discordance’ between 68Ga-DOTA-NOC PET/CT and 177Lu-DOTA-TATE posttherapy scan

Nuclear Medicine Communications, 2011
In this technical note, an unusual discordance between diagnostic and posttherapeutic scan resulting from the use of different somatostatin receptor ligands in two settings is described. Such observation, we believe, is multifactorial, but most importantly arises due to different receptor affinity profile of the ligands and different somatostatin ...
Sandip, Basu, Amit, Abhyankar, Purushottam, Kand, Rakesh, Kumar, Ramesh, Asopa, Mysore Govinda Ramakrishna, Rajan, Uday, Nayak, Hemant, Shimpi, Tapas, Das, Meera, Venkatesh, Sudipta, Chakrabarty, Sharmila, Banerjee   +11 more
openaire   +2 more sources

Bulk Scale Formulation of Therapeutic Doses of Clinical Grade Ready-to-Use ¹⁷⁷Lu-DOTA-TATE: The Intricate Radiochemistry Aspects

Cancer Biotherapy and Radiopharmaceuticals, 2017
177Lu-DOTA-TATE is a clinically useful and promising therapeutic radiopharmaceutical for peptide receptor radionuclide therapy of neuroendocrine tumors (NETs) overexpressing somatostatin receptors. Currently, the radiopharmaceutical is prepared in-house at nuclear medicine centers, thereby restricting its use to limited centers only.
Anupam, Mathur, Vrinda, Prashant, Navin, Sakhare, Sudipta, Chakraborty, K V, Vimalnath, Repaka Krishna, Mohan, Chanda, Arjun, Barkha, Karkhanis, Ravi, Seshan, Sandip, Basu, Aruna, Korde, Sharmila, Banerjee, Ashutosh, Dash, Satbir Singh, Sachdev   +13 more
openaire   +2 more sources